Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer

International Journal of Oncology

Volumn 12, Issue 3, 1998, Pages 553-563

  Huang, Cheng Long ^a   Taki, Toshihiko ^a   Adachi, Masashi ^a   Konishi, Takaaki ^a   Higashiyama, Masahiko ^b   Kinoshita, Moritoshi ^c   Hadama, Tohru ^c   Miyake, Masayuki ^a  

^a Kitano Hospital   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

K ras; Lung cancer; Mutation; p53

Indexed keywords

DNA; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATION RATE; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0031908238     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.3.553     Document Type: Article

References (42)

1. Statistics and Information Department: Vital Statistics 1993, Japan. Vol. 1. Ministry of Health and Welfare/Tokyo, pp274-279, 1995.
2. Takahashi T, Nau MM, Chiba I, Birrer, MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF and Minna JD: p53: a frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989.
3. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989.
4. Little CD, Nau MM, Carney DN, Gazdar AF and Minna JD: Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983.
5. Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R and Takahashi T: Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1-4, 1993.
6. Quinlan DC, Davidson AG, Summers CL, Warden HE and Doshi HM: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831, 1992.
7. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R and Shirakusa T: Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J Natl Cancer Inst 85: 2018-2023, 1993.
8. Ebina M, Steinberg SM, Mulshine JL and Linnoila RI: Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 54: 2496-2503, 1994.
9. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van Zandwijk N, Mooi WJ, Bos JL and Rodenhuis S: K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561-565, 1990.
10. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, Tolosa E, Armengol P, Barnadas A and Ariza A: Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 8: 2407-2412, 1993.
11. Rodenhuis S and Slebos RJ: Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52: 2665s-2669s, 1992.
12. b antigens with survival in patients with carcinoma of the lung. N Engl J Med 327: 14-18, 1992.
13. Levine AJ, Momand J and Finlay CA: The p53 tumor suppressor gene. Nature 351: 453-456, 1991.
14. Vogelstein B and Kinzler KW: p53 function and dysfunction. Cell 70: 523-526, 1992.
15. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-52, 1991.
16. Velculescu VE and El-Deiry WS: Biological and clinical importance of the p53 tumor suppressor gene. Clin Chem 42: 858-868, 1996.
17. Greenblatt MS, Bennett WP, Hollstein M and Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54: 4855-4878, 1994.
18. Lee JS, Yoon A, Kalapurakal SK, Ro JY, Lee JJ, Tu N, Hittelman WN and Hong WK: Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893-1903, 1995.
19. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC and Minna JD: Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603-1610, 1990.
20. TNM Classification of Malignant Tumors. 4th edition. Hermanek P and Sobin LH (eds). Springer-Verlag, Berlin, pp75-80, 1987.
21. Sambrook J, Fitsch EF and Maniatis T: Molecular cloning: A Laboratory Manual. Vol. 3. Cold Spring Harbor Laboratory Press, New York, ppE3-E4, 1989.
22. Hongyo T, Buzard GS, Palli D, Weghorst CM, Amorosi A, Galli M, Caporaso NE, Fraumeni JF and Rice JM: Mutations of the K-ras and p53 genes in gastric adenocarcinomas from a high-incidence region around Florence, Italy. Cancer Res 55: 2665-2672, 1995.
23. Orita M, Suzuki Y, Sekiya T and Hayashi K: Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5: 874-879, 1989.
24. Katsuragi K, Chiba W, Matsubara Y, Ikeda S, Ueta C and Kinoshita M: A sensitive and high-resolution method for the detection of mutations in the p53 gene using fluorescence-based PCR-SSCP. Biomed Res 16: 273-279, 1995.
25. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Amer Statist Assn 53: 457-481, 1958.
26. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1966.
27. Cox DR: Regression models and life-tables. J Roy Statist Soc Ser B Method 34: 187-220, 1972.
28. Cordon-Cardo C: Mutation of cell cycle regulators: biological and clinical implications for human neoplasia. Am J Pathol 147: 545-560, 1995.
29. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM and Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1989.
30. Chung GTY, Sundaresan V, Hasleton P, Rudd R, Taylor R and Rabbitts PH: Sequential molecular genetic changes in lung cancer development. Oncogene 11: 2591-2598, 1995.
31. Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Porta GD and Pierotti MA: Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 52: 6079-6082, 1992.
32. Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metcalf RA, Samet JM, Takeshima Y, Gu JR, Vahakangas KH, Soini Y, Paakko P, Welsh JA, Trump BF and Harris CC: p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53: 4817-4822, 1993.
33. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours (Review). Int J Oncol 7: 413-421, 1995.
34. Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes EC, Piantadosi S, Cordon-Cardo C and Slamon DJ: Inactivation of the retinoblastoma susceptibility gene in non-small cell lung cancer. The lung cancer study group. Oncogene 8: 1913-1919, 1993.
35. Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB and Cho KR: p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc Natl Acad Sci USA 91: 5320-5324, 1994.
36. Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R and Prives C: Wild-type p53 activates transcription in vitro. Nature 358: 83-86, 1992.
37. Yin Y, Tainsky MA, Bischoff FZ, Strong LC and Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70: 937-948, 1992.
38. Hartwell L: Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71: 543-546, 1992.
39. Stenger JE, Mayr GA, Mann K and Tegtmeyer P: Formation of stable p53 homotetramers and multiples of tetramers. Mol Carcinogen 5: 102-106, 1992.
40. Prives C: How loops, β-sheets and α helices help us to understand p53. Cell 78: 543-546, 1994.
41. Cho Y, Gorina S, Jeffrey PD and Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355, 1994.
42. Harris CC and Hollstein M: Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327, 1993.